Skip to main content

Articles By Meral K. El Ramahi, MD

PSA068.jpg

Novel TYK2 Inhibitor Efficacious for Treatment of Psoriatic Arthritis

By Meral K. El Ramahi, MD
07 June 2021

Dr. Philip Mease et al presented results of a phase II trial (OP0227) at EULAR 2021 that shows the efficacy and safety of an oral tyrosine kinase inhibitor (TYKi), deucravacitinib, for treatment of active psoriatic arthritis (PsA).

Read Article
computer screen safety

Ten-Year Analysis of Low-Dose Glucocorticoids in early RA

By Meral K. El Ramahi, MD
11 November 2020

Abstract #1998 by C. Roubille et al from Montpellier, France is a 10-year prospective analysis that looked at the risk of severe outcomes related to very low-dose glucocorticoid in early rheumatoid arthritis from the ESPOIR cohort.

Read Article
heart.jpg (keep)

FAST, FREED, CARES, & CONFIRMS: A Run-Down on the Black-Box Blues of Febuxostat

By Meral K. El Ramahi, MD
10 November 2020

Febuxostat, a nonpurine xanthine oxidase inhibitor used in the treatment of chronic gout to lower serum urate levels, received bad press in 2019 after the US Food and Drug Administration (FDA) placed a black-box warning on the medication’s label suggesting that it increases the risk of cardiovasc

Read Article
GCA temporal artery

Evolution of GCA Treatments - More to Come

By Meral K. El Ramahi, MD
08 November 2020

The field of Rheumatology is an ever-nascent field with an incredible expansion in our therapeutic armamentarium over the past half century.  An example of such advancement is easily appreciated when reflecting on the innovative treatment approach to Giant Cell Arteritis (

Read Article
×